Jazz Pharmaceuticals (NASDAQ:JAZZ) Director Bruce Cozadd Sells 3,500 Shares

Key Points

• Director Bruce Cozadd sold 3,500 shares of Jazz Pharmaceuticals at an average price of $140.00, reducing his stake by 0.85% to approximately 408,826 shares.
• The company reported a loss of ($8.25) EPS for the last quarter, falling short of analysts' expectations, despite achieving $1.05 billion in revenue.
• Analysts have mixed ratings on Jazz Pharmaceuticals, with several upgrades and a consensus target price of $178.93, indicating a Moderate Buy sentiment for the stock.

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Get Free Report) Director Bruce Cozadd sold 3,500 shares of the firm's stock in a transaction on Friday, October 3rd. The stock was sold at an average price of $140.00, for a total value of $490,000.00. Following the transaction, the director directly owned 408,826 shares of the company's stock, valued at $57,235,640. The trade was a 0.85% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Jazz Pharmaceuticals Price Performance

Jazz Pharmaceuticals stock traded up $2.27 during mid-day trading on Friday, hitting $139.48. 1,051,391 shares of the company were exchanged, compared to its average volume of 722,485. The company has a debt-to-equity ratio of 1.17, a current ratio of 1.62 and a quick ratio of 1.37. The business's 50 day simple moving average is $123.75 and its two-hundred day simple moving average is $115.84. The company has a market capitalization of $8.46 billion, a P/E ratio of -20.73, a PEG ratio of 8.51 and a beta of 0.28. Jazz Pharmaceuticals PLC has a 12-month low of $95.49 and a 12-month high of $148.06.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last announced its quarterly earnings data on Tuesday, August 5th. The specialty pharmaceutical company reported ($8.25) EPS for the quarter, missing analysts' consensus estimates of ($5.61) by ($2.64). The business had revenue of $1.05 billion during the quarter, compared to analysts' expectations of $1.05 billion. Jazz Pharmaceuticals had a negative net margin of 9.91% and a positive return on equity of 5.02%. Jazz Pharmaceuticals's revenue for the quarter was up 2.1% on a year-over-year basis. During the same period in the prior year, the firm earned $5.30 EPS. Jazz Pharmaceuticals has set its FY 2025 guidance at 4.800-5.600 EPS. Analysts forecast that Jazz Pharmaceuticals PLC will post 16.96 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on JAZZ shares. Zacks Research raised Jazz Pharmaceuticals from a "strong sell" rating to a "hold" rating in a research report on Friday, August 15th. Royal Bank Of Canada lifted their target price on Jazz Pharmaceuticals from $145.00 to $151.00 and gave the company an "outperform" rating in a report on Thursday, August 28th. Truist Financial lifted their target price on Jazz Pharmaceuticals from $200.00 to $205.00 and gave the company a "buy" rating in a report on Thursday, August 28th. Weiss Ratings reiterated a "sell (d)" rating on shares of Jazz Pharmaceuticals in a report on Saturday, September 27th. Finally, The Goldman Sachs Group lifted their target price on Jazz Pharmaceuticals from $162.00 to $185.00 and gave the company a "buy" rating in a report on Friday, August 29th. Fourteen investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $178.93.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of JAZZ. Teacher Retirement System of Texas lifted its stake in shares of Jazz Pharmaceuticals by 0.6% in the second quarter. Teacher Retirement System of Texas now owns 15,560 shares of the specialty pharmaceutical company's stock worth $1,651,000 after acquiring an additional 90 shares in the last quarter. Kendall Capital Management raised its stake in Jazz Pharmaceuticals by 1.2% during the first quarter. Kendall Capital Management now owns 7,964 shares of the specialty pharmaceutical company's stock valued at $989,000 after buying an additional 95 shares in the last quarter. Louisiana State Employees Retirement System raised its stake in Jazz Pharmaceuticals by 0.6% during the first quarter. Louisiana State Employees Retirement System now owns 16,900 shares of the specialty pharmaceutical company's stock valued at $2,098,000 after buying an additional 100 shares in the last quarter. Generali Investments Towarzystwo Funduszy Inwestycyjnych raised its stake in Jazz Pharmaceuticals by 8.7% during the second quarter. Generali Investments Towarzystwo Funduszy Inwestycyjnych now owns 1,250 shares of the specialty pharmaceutical company's stock valued at $133,000 after buying an additional 100 shares in the last quarter. Finally, Sound View Wealth Advisors Group LLC raised its stake in Jazz Pharmaceuticals by 1.3% during the first quarter. Sound View Wealth Advisors Group LLC now owns 8,425 shares of the specialty pharmaceutical company's stock valued at $1,046,000 after buying an additional 110 shares in the last quarter. Institutional investors and hedge funds own 89.14% of the company's stock.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.